Hidenori Nonaka

Group Manager
Rohto Pharmaceutical Co., Ltd.​
​Company Website: https://www.rohto.co.jp/global/​

Dr. Nonaka earned his Ph.D. from Graduate School of Science, The University of Tokyo in 2005. After completing postdoctoral research at the University of Tokyo and the Max Planck Institute of Molecular Cell Biology and Genetics, he joined Rohto Pharmaceutical Co., Ltd. in 2014. At Rohto, Dr. Nonaka has been actively engaged in the development of regenerative medicine products, focusing on therapies utilizing adipose-derived mesenchymal stromal cells. He has led non-clinical research efforts, advancing multiple pipelines for various target diseases. His work bridges cutting-edge research with innovative healthcare solutions in regenerative medicine.

Speech title & Synopsis

Advancing Regenerative Medicine from Japan to Asia: Product Development, CDMO Services, and Bioprocess Solutions 

Rohto Pharmaceutical Co., Ltd. is dedicated to contributing to the well-being of people worldwide. Guided by our mission to create a healthier and brighter future in healthcare, we are committed to making regenerative medicine a viable treatment option. In Japan, we are actively advancing the development of regenerative medicine products utilizing mesenchymal stromal cells (MSCs), with several pipelines already in clinical trials. With a vision of becoming a trusted leader in regenerative medicine by fostering collaboration with internal and external partners, Rohto aims to deliver reliable and transformative technologies globally.

In addition to product development, Rohto has established comprehensive CDMO (Contract Development and Manufacturing Organization) services to support partners in bringing their regenerative medicine products to market. Our expertise spans process development, manufacturing, quality control, and regulatory compliance, ensuring a seamless transition from research to commercialization.

We also provide bioprocess solutions tailored to the needs of regenerative medicine and cell therapy developers. These include animal-origin-free culture media for MSCs as well as automated cell manufacturing technologies designed to increase production consistency and ensure scalability. These solutions empower developers to deliver innovative therapies to patients more effectively.

This presentation will highlight Rohto’s contributions to advancing regenerative medicine across Japan and Asia. It will showcase our integrated approach to product development, CDMO services, and bioprocess innovation, underscoring our commitment to driving progress in this transformative field.

 

​